Debbie M Figueroa
Debbie M Figueroa has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Adam Stys
University of South Dakota Sanford School of Medicine, Sioux Falls, SD, USA
1 shared publication - Amanda Massmann
Sanford Imagenetics, Sanford Health, Sioux Falls, South Dakota, USA; Department of Internal Medicine, University of South Dakota School of Medicine, Vermillion, South Dakota, USA
1 shared publication - April Schultz
Sanford Imagenetics Sioux Falls South Dakota USA
1 shared publication - Joel Van Heukelom
Sanford Imagenetics, Sanford Health, Sioux Falls, SD 57105, USA
1 shared publication - Kurt Derek Christensen
PRecisiOn Medicine Translational Research (PROMoTeR) Center, Department of Population Medicine Harvard Pilgrim Health Care Institute Boston Massachusetts USA
1 shared publication - Max Weaver
Sanford Imagenetics Sanford Health Sioux Falls South Dakota USA
1 shared publication
Latest Publications
- 12 June 2024
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 25 (8-9) , 391-399
Evaluation of pharmacogenetic automated clinical decision support for clopidogrel
Aim: Clopidogrel requires CYP2C19 activation to have antiplatelet effects. Pharmacogenetic testing to identify patients with impaired CYP2C19 function can be coupled with clinical decision support (CDS) alerts to guide antiplatelet prescribing. We evaluated the impact of alerts on clopidogrel prescribing.Materials & methods: We retrospectively analyzed data for 866 patients in which CYP2C19-clopidogrel CDS was deployed at a single healthcare system during 2015-2023.Results: Analyses included 2,288 alerts. CDS acceptance rates increased from 24% in 2015 to 63% in 2023 (p < 0.05). Adjusted analyses also showed higher acceptance rates when clopidogrel had been ordered for a percutaneous intervention (OR: 28.7, p < 0.001) and when cardiologists responded to alerts (OR: 2.11, p = 0.001).Conclusion: CDS for CYP2C19-clopidogrel was effective in reducing potential drug-gene interactions. Its influence varied by clinician specialty and medication indications.
- 12 June 2024
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 25 (8-9) , 391-399
Evaluation of pharmacogenetic automated clinical decision support for clopidogrel
Aim: Clopidogrel requires CYP2C19 activation to have antiplatelet effects. Pharmacogenetic testing to identify patients with impaired CYP2C19 function can be coupled with clinical decision support (CDS) alerts to guide antiplatelet prescribing. We evaluated the impact of alerts on clopidogrel prescribing.Materials & methods: We retrospectively analyzed data for 866 patients in which CYP2C19-clopidogrel CDS was deployed at a single healthcare system during 2015-2023.Results: Analyses included 2,288 alerts. CDS acceptance rates increased from 24% in 2015 to 63% in 2023 (p < 0.05). Adjusted analyses also showed higher acceptance rates when clopidogrel had been ordered for a percutaneous intervention (OR: 28.7, p < 0.001) and when cardiologists responded to alerts (OR: 2.11, p = 0.001).Conclusion: CDS for CYP2C19-clopidogrel was effective in reducing potential drug-gene interactions. Its influence varied by clinician specialty and medication indications.